Sharma Ankur M, Khairnar Rahul, Kowalski Emily S, Remick Jill, Nichols Elizabeth M, Mohindra Pranshu, Yock Torunn, Regine William, Mishra Mark V
Radiation Oncology, University of Maryland School of Medicine, Baltimore, USA.
Pharmaceutical Health Services Research, University of Maryland, Baltimore, USA.
Cureus. 2019 Sep 19;11(9):e5703. doi: 10.7759/cureus.5703.
Objectives There has been a rapid increase in the number of one- and two-room proton beam therapy (PBT) centers, which may be limited in the number of patients they can treat. The objective of this study was to analyze the impact of the 'clinical benefit score' (CBS), utilized as a method for treatment prioritization for PBT operating in a 'cost-neutral' proton-photon payer environment. Materials & methods This study includes patients considered for PBT at a center that initially had only one or two treatment rooms available for clinical use. Patients were prospectively scored using the CBS, and higher scores were prioritized. The outcome was receipt of PBT and the independent variable was CBS. Crude and adjusted analyses were performed using logistic regression. Results There were 2163 patients evaluated. A total of 205 patients (9.5%) were deemed candidates for PBT, which was received by 122 (5.6%) patients. In patients considered for PBT, the mean CBS was 18.7. Patients who were <21 years old, female, non-Caucasian, receiving re-irradiation, and those with Medicare had a higher CBS. Multivariate analysis adjusting for insurance status revealed both CBS and insurance to be significant predictors for receiving PBT. A unit increase in CBS was associated with 1.04 times increased odds of receiving PBT (OR=1.04, 95%CI: 1.01-1.07, p=0.0145) and having Medicare was associated with 3.13 times increased odds of receiving PBT (OR=3.13, 95%CI: 1.57-6.26, p=0.0012). Subgroup analysis, which only included patients enrolled prior to opening the second gantry, showed 1.05 times increased odds of receiving PBT per unit increase in CBS (OR=1.05, 95%CI: 1.00-1.10, p=0.03) and 2.87 times increased odds of receiving PBT in patients with Medicare (OR=2.87, 95%CI: 1.04-7.92, p=0.04). Conclusion The CBS utilized was significantly associated with the receipt of PBT in a cost-neutral payer setting. Physicians may consider the use of CBS as a resource allocation tool.
目的 单室和双室质子束治疗(PBT)中心的数量迅速增加,但其可治疗的患者数量可能有限。本研究的目的是分析 “临床获益评分”(CBS)在 “成本中性” 的质子 - 光子支付环境下作为PBT治疗优先级确定方法的影响。材料与方法 本研究纳入了一家最初仅有一两个临床可用治疗室的中心考虑接受PBT治疗的患者。使用CBS对患者进行前瞻性评分,分数越高优先级越高。结局指标是是否接受PBT,自变量是CBS。采用逻辑回归进行粗分析和校正分析。结果 共评估了2163例患者。共有205例患者(9.5%)被认为是PBT的候选者,其中122例(5.6%)患者接受了PBT。在考虑接受PBT的患者中,CBS的平均值为18.7。年龄<21岁、女性、非白种人、接受再照射以及有医疗保险的患者CBS较高。调整保险状态后的多因素分析显示,CBS和保险都是接受PBT的显著预测因素。CBS每增加一个单位,接受PBT的几率增加1.04倍(OR = 1.04,95%CI:1.01 - 1.07,p = 0.0145),有医疗保险的患者接受PBT的几率增加3.13倍(OR = 3.13,95%CI:1.57 - 6.26,p = 0.0012)。仅纳入第二个机架启用前入组患者的亚组分析显示,如果CBS每增加一个单位,接受PBT的几率增加1.05倍(OR = 1.05,95%CI:1.00 - 1.10,p = 0.03),有医疗保险的患者接受PBT的几率增加2.87倍(OR = 2.87,95%CI:1.04 - 7.92,p = 0.04)。结论 在成本中性的支付环境下,所使用的CBS与接受PBT显著相关。医生可考虑将CBS用作资源分配工具。